24 August 2016 - New treatment for patients with advanced colorectal cancer.

Servier UK today announced that, following a single technology appraisal, NICE has issued final guidance recommending Lonsulf (trifluridine with tipiracil hydrochloride), for the treatment of adult patients with metastatic colorectal cancer (bowel cancer) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents for use within England.

This announcement comes at a time when there is a real need for further treatment options for patients with refractory metastatic colorectal cancer, or what may also be referred to as advanced bowel cancer. In light of the changing funding landscape for oncology agents within the UK, the addition of new products in later lines of therapy could be crucial to those patients.

Servier welcomes NICE’s decision and the positive news it brings for patients with metastatic colorectal cancer and their families. The decision by NICE arrives four months after the European Commission granted trifluridine/tipiracil a Marketing Authorisation and represents a milestone in Servier’s evolution. Servier is an international pharmaceutical company, with no shareholders, governed by a non-profit Foundation.

Read Servier press release